These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39222024)

  • 21. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C.
    Kim YJ; Jung J; Joo JH; Kim SY; Kim JH; Lim YS; Lee HC; Kim JH; Yoon SM
    Radiother Oncol; 2019 Dec; 141():95-100. PubMed ID: 31506181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma.
    Lee WC; Hung HC; Lee JC; Wang YC; Cheng CH; Wu TH; Lee CF; Wu TJ; Chou HS; Chan KM
    Cancer Rep (Hoboken); 2021 Feb; 4(1):e1294. PubMed ID: 33048465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients.
    Guan HT; Wang J; Yang M; Song L; Tong XQ; Zou YH
    Chin Med J (Engl); 2013; 126(19):3651-5. PubMed ID: 24112158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients.
    Elwan N; Salem ML; Kobtan A; El-Kalla F; Mansour L; Yousef M; Al-Sabbagh A; Zidan AA; Abd-Elsalam S
    Immunol Invest; 2018 Feb; 47(2):169-180. PubMed ID: 29182438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
    Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Zhang G; Xiao Y; Tan J; Liu H; Fan W; Li J
    J Transl Med; 2024 Jun; 22(1):543. PubMed ID: 38844930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
    Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
    Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review.
    Zhao Y; Cai G; Zhou L; Liu L; Qi X; Bai M; Li Y; Fan D; Han G
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):357-64. PubMed ID: 23714021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
    Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
    Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
    Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
    Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
    Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.